Keyon Lab is a pharma biotech start-up company founded in 2026 to develop novel therapeutics for neuropsychiatric disorders acting on specific classes of ion channels.
The team spans a wide range of professional experience, ranging from internationally-recognized and well-established academic team leaders to enthusiastic and highly-motivated early-career investigators.
Entirely based in southern Italy, a highly-fertile and “volcanic” territory, Keyon Lab will dedicate its energies to translate innovative discoveries into therapeutic opportunities for both rare and common diseases.